UPDATE: Oppenheimer Starts F-Star Therapeutics Inc. (FSTX) at Outperform

April 15, 2021 4:03 PM EDT
Get Alerts FSTX Hot Sheet
Price: $7.13 -19.62%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 38 | Down: 18 | New: 7
Trade Now! 
Join SI Premium – FREE
(Updated - April 15, 2021 4:07 PM EDT)

Oppenheimer analyst Jartaj Singh initiates coverage on F-Star Therapeutics Inc. (NASDAQ: FSTX) with a Outperform rating and a price target of $30.00.

The analyst comments "We are initiating coverage on F-star Therapeutics (FSTX) with an Outperform rating and a $30 PT. We believe FSTX screens well among various bispecific antibody (BsAbs) platforms evolving rapidly in the past two years, given the company platform's ability to leverage the three key features of BsAbs: conditionality/crosslinking/clustering through its molecules' Fc-gamma receptor (FcγR) independent tetravalent binding and generate uncorrelated high-value oncology assets. In our opinion, FSTX's story has checked the boxes for: (1) a biomarker-driven targeted oncology approach identifying a patient population subset that allows accelerated approval; (2) enhanced risk/benefit profile with low immunogenicity/high-affinity target engagement/no hook effect/etc.; (3) unveiling novel target synergy unattainable by mAbs combination; and (4) experienced/execution-focused management. We are bullish on the story."

For an analyst ratings summary and ratings history on F-Star Therapeutics Inc. click here. For more ratings news on F-Star Therapeutics Inc. click here.

Shares of F-Star Therapeutics Inc. closed at $9.85 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage